FDA Grants Fast Track Designation to Debio 1347 for Unresectable or Metastatic Tumors With a Specific FGFR Gene Alteration

May 11, 2018 – Debiopharm International SA (Debiopharm) recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Debio 1347, an inhibitor of fibroblast growth factor receptors 1, 2, and 3 (FGFR1–3), for the treatment of patients with unresectable or metastatic tumors with a specific FGFR gene alteration. The FDA’s Fast Track designation facilitates the development of new therapies that treat serious conditions and … (leggi tutto)